Shares of Blueprint Medicines Corp. (BPMC) gained over 12% in the after-hours session on Wednesday, following encouraging early data from its ongoing phase I trial of BLU-285 in patients with advanced gastrointestinal stromal tumors, or GIST.
from RTT - Biotech http://ift.tt/2fNWN2C
via IFTTT
No comments:
Post a Comment